Overview

PKC412 and 5-Azacytidine

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if the combination of PKC412 (also called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute leukemia and MDS. The safety and best dose of the combination of the drugs will also be studied.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Celgene Corporation
Novartis Pharmaceuticals

Treatments:

4'-N-benzoylstaurosporine
Azacitidine
Midostaurin
Staurosporine